Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer
Vishnu Prasath, H. Boutrid, Robert Wesolowski, Mahmoud Abdel‐Rasoul, Cynthia Timmers, Maryam B. Lustberg, Rachel M. Layman, Erin Macrae, Ewa Mrózek, Charles L. Shapiro, Kristyn Glover, Mark Vater, G. Thomas Budd, Lyndsay N. Harris, Claudine Isaacs, Claire Dees, Charles M. Perou, Gary L. Johnson, Andrew Poklepovic, Helen X. Chen, Miguel A. Villalona‐Calero, William E. Carson, Daniel G. Stover, Bhuvaneswari Ramaswamy
Topics & Concepts
TrametinibMedicineInternal medicineBreast cancerTriple-negative breast cancerOncologyMEK inhibitorPhases of clinical researchCombination therapyClinical trialMetastatic breast cancerChemotherapyCancerMAPK/ERK pathwayCell biologyKinaseBiologyMelanoma and MAPK PathwaysPI3K/AKT/mTOR signaling in cancerLung Cancer Treatments and Mutations